Literature DB >> 12533838

Papillary carcinoma of the thyroid: evidence for a role for hepatocyte growth factor (HGF) in promoting tumour angiogenesis.

Stefania Scarpino1, Francesca Cancellario D'Alena, Arianna Di Napoli, Francesca Ballarini, Maria Prat, Luigi P Ruco.   

Abstract

The pattern of vascularization of papillary carcinoma was investigated in tumour sections from 31 cases and in primary cultures from 12 cases. Tumour sections were immunostained for von Willebrand Factor (vWF) to visualize blood vessels; for endothelial-specific nitric-oxide-synthase (EC-NOS), as a marker of endothelial cell activation; and for Ki-67 to evaluate endothelial cell proliferation. It was found that endothelial cells lining venous vessels located in peritumoural fibrous tissue were intensely EC-NOS-positive and occasionally Ki-67-positive. Capillary vessels of tumour papillae were not stained for Ki-67 and were weakly EC-NOS-positive. Primary cultures of papillary carcinoma cells were used as a potential source of factors active on endothelial cells. It was found that thyroid tumour cells contain RNAs for angiopoietin, vascular endothelial growth factor (VEGF), and VEGF-C; moreover, they release large amounts of VEGF into culture supernatants and exert chemotactic activity in vitro for the endothelial cell line SIEC. The ability of papillary carcinoma cells to release angiogenic factors could be stimulated in vitro. Hepatocyte growth factor (HGF; 25 ng/ml) induced a 1.2- to 5-fold increase in the amount of VEGF released by tumour cells and a 1.2- to 4.2-fold increase in the amount of chemotactic activity present in culture supernatants. Met protein, the high affinity HGF-receptor, is overexpressed in a large proportion of cases of papillary carcinoma. These findings are consistent with the possibility that HGF-Met protein interaction is one of the molecular mechanisms promoting the vascularization of papillary carcinoma of the thyroid. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12533838     DOI: 10.1002/path.1278

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  10 in total

Review 1.  Microenvironment of liver regeneration in liver cancer.

Authors:  Han-Min Li; Zhi-Hua Ye
Journal:  Chin J Integr Med       Date:  2017-05-18       Impact factor: 1.978

2.  Anti-angiogenic Therapy for Retinal Disease.

Authors:  Yannis M Paulus; Akrit Sodhi
Journal:  Handb Exp Pharmacol       Date:  2017

3.  Discrimination of benign and malignant thyroid nodules by molecular profiling.

Authors:  David J Finley; Baixin Zhu; Catherine B Barden; Thomas J Fahey
Journal:  Ann Surg       Date:  2004-09       Impact factor: 12.969

4.  RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation.

Authors:  Giuliana Cassinelli; Enrica Favini; Debora Degl'Innocenti; Alessandro Salvi; Giuseppina De Petro; Marco A Pierotti; Franco Zunino; Maria Grazia Borrello; Cinzia Lanzi
Journal:  Neoplasia       Date:  2009-01       Impact factor: 5.715

5.  Serum hepatocyte growth factor is increased in Hashimoto's thyroiditis whether or not it is associated with nodular goiter as compared with healthy non-goitrous individuals.

Authors:  R M Ruggeri; S Sciacchitano; A Vitale; P Cardelli; M Galletti; E Vitarelli; G Barresi; S Benvenga; F Trimarchi; M Trovato
Journal:  J Endocrinol Invest       Date:  2009-03-25       Impact factor: 4.256

6.  Hypoxia-inducible factor in thyroid carcinoma.

Authors:  Natalie Burrows; Muhammad Babur; Julia Resch; Kaye J Williams; Georg Brabant
Journal:  J Thyroid Res       Date:  2011-06-16

7.  The tyrosine kinase receptor c-met, its cognate ligand HGF and the tyrosine kinase receptor trasducers STAT3, PI3K and RHO in thyroid nodules associated with Hashimoto's thyroiditis: an immunohistochemical characterization.

Authors:  R M Ruggeri; E Vitarelli; G Barresi; F Trimarchi; S Benvenga; M Trovato
Journal:  Eur J Histochem       Date:  2010-06-03       Impact factor: 3.188

Review 8.  Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives.

Authors:  Ricardo Costa; Benedito A Carneiro; Sunandana Chandra; Sachin G Pai; Young Kwang Chae; Jason B Kaplan; Hannah B Garrett; Mark Agulnik; Peter A Kopp; Francis J Giles
Journal:  Drug Des Devel Ther       Date:  2016-02-29       Impact factor: 4.162

Review 9.  The Pathogenetic Role of the HGF/c-Met System in Papillary Carcinoma of the Thyroid.

Authors:  Luigi Ruco; Stefania Scarpino
Journal:  Biomedicines       Date:  2014-10-24

Review 10.  Angiogenesis in Malignant Thyroid Tumors.

Authors:  Matvey Vladimir Sprindzuk
Journal:  World J Oncol       Date:  2011-01-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.